ASMB vs XOMA

ASMB's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the company exhibits strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, suggesting potential operational turnaround. However, negative profitability metrics—such as a -103.65% profit margin and negative ROE—highlight persistent losses. The stock trades at a premium valuation (Price/Sales of 11.96) with no dividend, reflecting high growth expectations rather than intrinsic value. Analysts maintain a target price of $47.75, implying upside, but consensus is weak with only four analysts.

XOMA exhibits a stark divergence between deterministic value metrics and market momentum. With a weak Piotroski F-Score of 3/9 and a current price ($37.89) trading significantly above its Graham Number ($15.24) and Intrinsic Value ($10.22), the stock is fundamentally overvalued by traditional standards. However, exceptional profit margins (60.81%) and strong YoY revenue growth (57.9%) support a growth narrative, further bolstered by a high analyst target of $65.75. The overall profile is that of a high-risk, high-reward royalty play with poor traditional health scores but strong operational efficiency.